Paul L Berns
Director at Kardigan, Inc. (KARD); 10% Owner at Lyell Immunopharma, Inc. (LYEL); See Remarks at Neumora Therapeutics, Inc. (NMRA)
Purchase track record
Below average. Based on 2 purchases with a full 90 days of price history.
4
Avg. 90-day return-38.5%
vs. S&P 500-46.1%
Beat the market0%
Paper profit on buys−$9.9M
Total bought / sold$32.5M / $34K
Reported trades
| Filed | Stock | Type | Shares | Price | Value | Since |
|---|---|---|---|---|---|---|
| Jun 24SEC | KARDKardigan, Inc. | Buy | 1,250,00015,042,035 held (+9%) | $16.00 | $20.0M | -8.3% |
| Mar 9SEC | LYELLyell Immunopharma, Inc. | Buy | 488,0901,426,528 held (+52%) | $25.61 | $12.5M | -66.0% |
| Feb 19SEC | NMRANeumora Therapeutics, Inc. | Sell | 9,8197,395,185 held (−0%) | $3.51 | $34K | -86.4% |
- Buy
Director Paul L Berns bought $20.0M of KARD at $16.00 — first open-market purchase in our records.
- Buy
10% Owner Paul L Berns bought $12.5M of LYEL at $25.61 — first open-market purchase in our records; raises the stake by 52%.